Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial

Neurofibromatosis Type 1 (NF1) plexiform neurofibromas (PN) are progressive, multicellular neoplasms that cause morbidity and predispose to sarcoma. Treatment of Nf1(flox/flox);PostnCre mice with cabozantinib, an inhibitor of multiple tyrosine kinases, caused a reduction in PN size and number and di...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Med
Autori principali: Fisher, Michael J., Shih, Chie-Schin, Rhodes, Steven D., Armstrong, Amy E., Wolters, Pamela L., Dombi, Eva, Zhang, Chi, Angus, Steven P., Johnson, Gary L., Packer, Roger J., Allen, Jeffrey C., Ullrich, Nicole J., Goldman, Stewart, Gutmann, David H., Plotkin, Scott R., Rosser, Tena, Robertson, Kent A., Widemann, Brigitte C., Smith, Abbi E., Bessler, Waylan K., He, Yongzheng, Park, Su-Jung, Mund, Julie A., Jiang, Li, Bijangi-Vishehsaraei, Khadijeh, Robinson, Coretta Thomas, Cutter, Gary R., Korf, Bruce R., Blakeley, Jaishri O., Clapp, D. Wade
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8275010/
https://ncbi.nlm.nih.gov/pubmed/33442015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-020-01193-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi